Coagulation factor X (FX)-binding ablated adenovirus type 5 (Ad5) vectors have been genetically engineered to ablate the interaction with FX, resulting in substantially reduced hepatocyte transduction following intravenous administration in rodents. Here, we quantify viral genomes and gene transfer mediated by Ad5 and FX-binding-ablated Ad5 vectors in non-human primates. Ad5 vectors accumulated in and mediated gene transfer predominantly to the liver, whereas FX-binding-ablated vectors primarily targeted the spleen but showed negligible liver gene transfer. In addition, we show that Ad5 binding to hepatocytes may be due to the presence of heparan sulfate proteoglycans (HSPGs) on the cell membrane. Therefore, the Ad5-FX-HSPG pathway mediating liver gene transfer in rodents is also the mechanism underlying Ad5 hepatocyte transduction in Microcebus murinus.
Following intravenous (i.v.) administration adenovirus type 5 (Ad5) viral particles predominantly accumulate in and transduce the liver in rodent and non-human primate models. [1] [2] [3] Although the coxsackie and adenovirus receptor (CAR) acts as a primary receptor for Ad5 in vitro, modifications of the Ad5 capsid ablating the interaction with CAR and/or its secondary receptors (avb3 and avb5 integrins) do not alter the biodistribution of Ad5 following i.v. delivery. [4] [5] [6] Several studies have documented the role of blood coagulation factors in mediating liver gene transfer in vivo and the mechanism underlying Ad5 hepatocyte transduction. [7] [8] [9] [10] [11] [12] We demonstrated that coagulation factor X (FX) binds to the hexon protein of Ad5 at high affinity (B2 nM) and that this interaction mediates hepatocyte transduction following i.v. delivery in mice and rats. 11 FX-binding-ablated Ad5 vectors have been mutated in the hexon hyper-variable region (HVR)5 (T270P and E271G) and/or HVR7 (I421G, T423N, E424S, L426Y and E451Q) as described previously 7 and showed substantially reduced hepatocyte transduction following i.v. administration in rodent models. 7, 13 Recently, our group has highlighted the importance of heparan sulfate proteoglycans (HSPGs) as receptors for the Ad5-FX complex and the requirement of the integrin binding motif Arg-GlyAsp (RGD) for efficient uptake, internalization and correct trafficking when Ad5 vectors use this pathway. 14 However, many other interactions and anatomical features, including fenestrae size in liver sinusoids and interactions with key tropismdetermining capsid proteins, can differ between different species. 15 Limited data obtained from necropsies in human clinical trials suggest that Ad5 may target the liver and spleen after i.v. administration, 16 although definitive data have not been reported from previous or ongoing clinical trials. However, several studies performed in non-human primates have shown that Ad5 primarily transduces the liver and spleen following i.v. delivery. 3,17-23 Ablation of CAR-and integrin-binding motifs in the Ad5 capsid did not alter Ad5 biodistribution in cynomolgus monkeys, indicating that an alternate transduction pathway may be responsible for liver transduction in these animals. 19 Alternative serotypes (Ad35) have also shown decreased liver transduction following i.v. delivery in non-human primates, although viral genomes can be detected in hepatic samples. 24 Other studies have obtained similar results using fiber-pseudotyped Ad5 vectors (Ad5/35 and Ad5/11) where significant gene transduction by these vectors was only observed in the marginal zone of splenic follicles. 18 Importantly, none of the reported modifications incorporated in the Ad5 capsid, via ablation of fiber and/or penton binding to natural receptors, 19 have shown significantly reduced hepatic transduction or viral genome accumulation in non-human primates. In the present study, we document the transduction profiles and viral genome accumulation of Ad5 and FX-binding-ablated Ad5 vectors in Microcebus murinus to identify whether the Ad5-FX pathway modulates Ad5 biodistribution in non-rodent species. M. murinus is a small primate with an approximate body weight of 90 g. This species is a pro-simian, closer to human than to rodents. The use of this model has become more popular essentially for ethical reasons and the restrictions reflected in the European guidelines with regard to primate research. In addition, M. murinus breed easily up to the age of 14 years and have litters every 8 months, with between two and three offspring per litter. To evaluate the biodistribution of these viruses 48 h after i.v. delivery, anesthetized animals were injected intravenously with 1Â10 11 vp per animal of Ad5 (4.4Â10 11 pfu ml À1 , 5.26Â10 12 vp ml À1 vp:pfu¼11.95) and FX-binding-ablated Ad5-HVR5*7*E451Q (1.25Â10 11 pfu ml À1 , 4.3Â10 12 vp ml À1 vp:pfu¼ 34.4) vectors (approximately 1Â10 12 vp kg À1 ). Animals were killed 48 h later and tissues harvested for analysis. All animal experimentation was approved by the local ethics committee (authorization no.
CEEA-LR-1013) in accordance with the European Community Council directives of 24 November 1986. The dose used in this study (1Â10 12 vp kg À1 ) has been proved to be safe in previous studies with Ad5 vectors and non-human primates. 25 Doses above 1Â10 13 vp kg À1 have been lethal in baboons 17 and highly toxic (owing to hepatic transaminitis) in rhesus monkeys. 25 Viral genome accumulation was quantified using SyBR green real-time PCR (7900HT Sequence Detection System, Applied Biosystems, Paisley, UK) using 100 ng of purified DNA and 0.2 mM hexon primers (5¢-CGCGGTGCGGCTGGTG-3¢ and 5¢-TGGCGCATCCCATTCTCC-3¢) as previously described. 7 DNA was extracted from tissues using the QIAamp DNA mini kit (QIAGEN, Crawley, UK), following the manufacturer's instructions. As shown in Figure 1 , Ad5 accumulated mainly in the liver although viral genomes were also detected in the spleen, heart, lung and kidney. In addition, we also detected low levels of viral genomes in the thymus, pancreas, intestines and lymph nodes. Importantly and in agreement with previous results, 13 the FX-binding-ablated Ad5CMVlacZ-HVR5*7*E451Q vector showed significantly reduced accumulation in the liver and was found primarily in the spleen (Figure 1 ). In addition, negligible levels of Ad5CMVlacZ-HVR5*7*E451Q viral genomes were detected in most of the tissues analyzed ( Figure 1 ). Importantly, these results suggest that the Ad5-FX pathway may mediate viral genome accumulation not only in the liver but also in the majority of the organs analyzed, indicating the presence of HSPGs on the surface of targeted cells.
To test if viral genome accumulation correlated with gene transfer, b-galactosidase (b-gal) protein quantification was carried out using the b-Gal enzyme-linked immunosorbent assay (ELISA) kit (Roche, Mannheim, Germany) according to the manufacturer's instructions. In concordance with the biodistribution data, Ad5 vectors efficiently transduced the liver with lower levels of detection in the rest of the organs analyzed (Figure 2 ). Of note, although high levels of viral genomes were found in several organs (spleen, heart, lung and kidney) including the liver, the levels of transduction were substantially lower for these organs, in agreement with results obtained previously. 13 Contrary to Ad5CMVlacZ, FX-binding-ablated Ad5 vectors (Ad5CMVlacZ-HVR5*7*E451Q) presented significantly lower levels of transduction in the liver and limited levels of transduction in the spleen as previously observed in rodent models at similar doses. 7, 13 Interestingly, only basal levels of transduction were observed for Ad5CMVlacZ-HVR5*7*E451Q in the majority of tissues analyzed, with the exception of the spleen (Figure 2) . In order to confirm and visualize the b-gal expression of Ad5CMVlacZ, we performed histochemical analysis in the livers and spleens of non-human primates 48 h post-injection. Livers and spleens were embedded in OCT (Tissue-Tek; Sakura Finetek Europe BV, Alphen aan den Rijn, The Netherlands), and frozen at À80 1C immediately after necropsy. Sixmicrometer liver sections were analyzed by immunohistochemistry using the rabbit anti-b-galactosidase polyclonal antibody (8.4 mg ml À1 ; MP Biomedicals, Illkirch, France) or matched rabbit IgG non-immune control (8.4 mg ml À1 ; Invitrogen, Paisley, UK) and then detected using an Alexa-488 fluorescent anti-rabbit polyclonal antibody (Invitrogen). Frozen sections were blocked for 30 min in 10% normal goat serum (GS) (Vector Laboratories, Peterborough, UK). Primary antibodies were incubated with sections for 16 h at 4 1C, followed by secondary antibody incubation (diluted 1:500 in PBS+Tween 0.05% with 2% GS) and incubated for 1 h at room temperature. Slides were mounted with ProLong Gold+4¢,6-diamidino-2-phenylindole (Invitrogen) and images were captured using an Olympus BX60 fluorescence microscope and analyzed using Cell M software (Olympus, Southend-on-Sea, UK). The percentage of b-gal-positive cells per 40Â field (n¼8) was visually quantified using Cell M software (Olympus). As previously observed, 13 animals injected with Ad5CMVlacZ exhibited high levels of hepatocyte transduction, whereas very low levels of b-gal expression were detected in liver sections from animals injected with Ad5CMVlacZ-HVR5*7*E451Q vectors (Figure 3, upper panel) . Negligible levels of b-gal were observed in spleen sections from both Ad5CMVlacZ and FX-binding-ablated Ad5CMVlac-HVR5*7*E451Q (Figure 3, upper panel) . Quantification of b-gal-positive cells showed a significant decrease in hepatocyte transduction by Ad5CMVlacZ-HVR5*7*E451Q compared with Ad5CMVlacZ, while similar, low levels of splenic cell transduction were observed for both viruses (Figure 3, lower panel) . In summary, transduction profiles and immunohistochemical studies correlated with the levels of viral genomes detected in the liver. Importantly, this work identifies the FX pathway as the main mechanism of gene transfer to hepatocytes following i.v. delivery of Ad5 particles in M. murinus.
Several studies have shown that following i.v. delivery in rodents, the Ad5-FX complex interacts with HSPGs on the surface of hepatocytes. 8, 9, 26 Recently, our group has studied the receptors used by the Ad5-FX complex in vitro and in vivo 14 in greater detail. This interaction is dependent on the sulfation of the HS chains, which interact with the serine protease domain of the FX molecule. We also showed that pre-inoculation with highly sulfated heparin reduced the Ad5CMVlacZ-HVR5*7*E451Q I n t e s t i n e s P a n c r e a s H e a r t K i d n e y L u n g S p l e e n Figure 2 Transduction profiles of Ad5CMVlacZ and FX-binding-ablated Ad5CMVlacZ-HVR5*7*E451Q vectors at late time points (48 h). b-Galactosidase protein expressed from viral vectors was quantified using the b-gal ELISA assay (Roche) from non-human primate (M. murinus) samples following the i.v. injection of 1Â10 11 vp per animal. Statistics were performed with natural log values using one-way ANOVA (*Po0.05 vs Ad5CMVlacZ, n¼5).
Coagulation factor X mediates adenovirus type 5 liver gene transfer R Alba et al accumulation of Ad5 vectors in the livers of macrophage-depleted MF1 mice. To investigate whether this mechanism was also present in non-human primates, frozen sections from M. murinus were incubated with 1Â10 8 vp of Alexa488-labelled Ad5CMVLacZ or Ad5CMVlacZ-HVR5*7*E451Q in serum-free medium in the presence or absence of 10 mg ml À1 of FX and/or increasing concentrations of heparin for 1 h on ice. Sections were washed twice with PBS and mounted using ProLong Gold antifade reagent with 4¢,6-diamidino-2-phenylindole. Sections were then imaged using an Olympus CellM fluorescent imaging system. Adenoviruses were labeled using an Alexa Fluor-488 protein labeling kit (Invitrogen) according to the manufacturer's instructions as described previously. 14 As shown in Figure 4 , labeled Ad5CMVLacZ particles efficiently bind to hepatocytes in the presence of FX. Under these conditions, pre-treatment with increasing doses of heparin blocks the binding of Ad5CMVLacZ particles to hepatocytes. Doses of 12.5 mg ml À1 of heparin completely prevented the binding of labeled Ad5CMVLacZ particles to liver slices ( Figure 4) . Conversely, no labeled Ad5CMVlacZ-HVR5*7*E451Q particles bound the surface of liver sections in the presence or absence of FX. These results indicate that the Ad5-FX entry pathway in microcebes may also require the presence of HSPGs on the surface of hepatocytes.
During the last decade, there have been many efforts to retarget Ad5 vectors from the liver to other tissues. Nevertheless, the ablation of CAR-and integrin-binding motifs did not reduce Ad5-mediated liver gene transfer following i.v. delivery. 4, 5, 19 FX-binding-ablated Ad5 vectors have shown substantially reduced hepatocyte transduction in mice and rats following i.v. delivery. 13 However, this is the first time to our knowledge that Ad5 vectors have been detargeted from the liver in a non-human primate model. Here, we show significant liver detargeting of FX-binding-ablated Ad5 vectors with minimal modifications in the Ad5-hexon protein (two amino acids in HVR5 and five amino acids in HVR7). In accordance with our previous studies in mice and rats, these vectors accumulated primarily in the spleen. However, the levels of microcebe spleen transduction by FX-binding-ablated Ad5 vectors were lower than Ad5CMVlacZ. This is not due to an impairment of transduction by Ad5CMVlacZ-HVR5*7*E451Q, as we have previously shown similar levels of non-FX-mediated transduction in vitro and of muscle tissue in vivo by these vectors and control Ad5 vectors. 13 Previous studies have shown that there is a loss of spleen white pulp following i.v. administration of Ad5 vectors in non-human primates (rhesus monkeys), but only at substantially higher doses than the dose used in the present study (7.5Â10 12 vp kg À1 ). Previous studies have shown that sequestration of Ad5 vectors by liver macrophages leads to a 'threshold effect' on hepatocyte transduction, with significant attenuation of hepatocyte transduction at low doses (o1Â10 12 vp kg À1 ). 2 Here we show significant levels of liver transduction by Ad5, indicating that the dose used is probably on or above the threshold for saturation of Kupffer cells. The varying size of fenestrated capillaries between different species (for example, in humans 107±1.5 nm) is also an important issue to take into account when Ad5 is administered intravenously. 15, 27 The present study indicates that the fenestrated capillaries of non-human primates did not impair hepatocyte transduction by Ad5 following i.v. delivery. Moreover, the high levels of Ad5 viral genomes found in other organs (spleen, lung, kidney and heart) indicate the size of fenestrated capillaries present in M. murinus did not restrict the extravasation of circulating Ad5 particles. Interestingly, there was a significant reduction in the quantity of FX-binding-ablated vectors found in the majority of organs analysed compared with Ad5, indicating that the Ad5-FX pathway may modulate transduction of organs other than those previously reported (liver and spleen). 14 Finally, we showed that heparin was able to competitively inhibit binding of Ad5-FX complexes to microcebe liver slices. No binding of FX-binding-ablated vectors to microcebe liver slices was observed. Taken together, these results indicate that HSPGs may be involved in the primary interaction of Ad5 with the cell surface of microcebe hepatocytes.
Studies have shown that the Ad5 capsid interacts with CAR receptors expressed on the surface of human and rat erythrocytes via its fiber knob domain. 28, 29 Removal of the fiber knob CAR-binding motif in combination with FX-binding ablation may therefore improve the in vivo biodistribution of Ad5 vectors in non-human primates. This may also result in enhanced vector detargeting/retargeting, as replacement of the fiber in FX-binding-ablated Ad5 vectors by an Ad35 fiber (which binds CD46 with high affinity) significantly improves lung targeting in CD46+ transgenic mice. 13 In conclusion, these results have implications for Ad5 liver targeting in humans and detargeting strategies based on FX-binding ablated Ad5 vectors. 
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Ad5-HVR5*7*E451Q-FX 2.5 g/ml 12.5 g/ml 50 g/ml Ad5+FX +heparin 10 m Figure 4 Binding of the Ad5-FX complex to M. murinus liver slices following heparin pre-treatment at increasing doses. Six-micrometer liver sections from microcebes were incubated with 1Â10 8 vp of Alexa488-labelled Ad5CMVLacZ ('Ad5') or Ad5CMVLacZ-HVR5*7*E451Q ('Ad5-HVR5*7*E451Q') (green) in the presence or absence of 10 mg ml À1 FX and increasing concentrations of heparin for 1 h at 4 1C for the Ad5CMVlacZ vector.
